Fate Therapeutics, Inc. (NASDAQ:FATE) Given Average Rating of “Hold” by Brokerages

Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) have been assigned an average rating of “Hold” from the eight analysts that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $3.30.

Several research analysts have recently weighed in on FATE shares. Wall Street Zen upgraded shares of Fate Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, August 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of Fate Therapeutics in a report on Thursday, June 12th. Wells Fargo & Company reduced their target price on shares of Fate Therapeutics from $4.00 to $2.50 and set an “equal weight” rating for the company in a report on Wednesday, August 13th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Fate Therapeutics in a report on Saturday, September 27th.

Fate Therapeutics Stock Performance

Shares of FATE stock opened at $1.21 on Monday. Fate Therapeutics has a 1 year low of $0.66 and a 1 year high of $3.50. The firm’s fifty day moving average price is $1.06 and its two-hundred day moving average price is $1.11. The firm has a market capitalization of $139.55 million, a P/E ratio of -0.83 and a beta of 2.34.

Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings data on Tuesday, August 12th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.06. The company had revenue of $1.91 million for the quarter, compared to analyst estimates of $1.16 million. Fate Therapeutics had a negative net margin of 2,025.05% and a negative return on equity of 50.95%. As a group, equities research analysts forecast that Fate Therapeutics will post -1.63 EPS for the current fiscal year.

Institutional Trading of Fate Therapeutics

A number of institutional investors have recently bought and sold shares of FATE. Savant Capital LLC bought a new stake in Fate Therapeutics in the 2nd quarter valued at about $27,000. Bridgeway Capital Management LLC bought a new stake in Fate Therapeutics in the 2nd quarter valued at about $28,000. CWM LLC boosted its holdings in Fate Therapeutics by 899.6% in the 1st quarter. CWM LLC now owns 41,435 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 37,290 shares during the period. Caption Management LLC bought a new stake in Fate Therapeutics in the 1st quarter valued at about $45,000. Finally, Jane Street Group LLC boosted its holdings in Fate Therapeutics by 106.9% in the 1st quarter. Jane Street Group LLC now owns 63,691 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 32,911 shares during the period. Institutional investors own 97.54% of the company’s stock.

About Fate Therapeutics

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.